Abstract
Background Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel highly effective CFTR modulator combination proven to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions of abdominal symptoms (AS) in German, British and Irish pwCF after 24-26 weeks of ETI using the CFAbd-Score, the first PROM specifically developed and validated for pwCF following FDA guidelines. Notably, many pwCF reported marked changes in their AS during the first days of the new treatment. To capture these immediate effects, we developed the CFAbd-day2day, a CF-specific GI-diary, following FDA and COSMIN guidelines.
Aims To prospectively capture immediate dynamics of AS using the CFAbd-day2day 14 days before and 14-28 days after ETI initiation. In addition, we aim here to provide validation steps of the novel PROM concerning sensitivity to changes.
Methods To develop the CFAbd-day2day, focus groups (community voice=pwCF and their proxies and CF specialists from different fields) were repeatedly consulted. Before and under the new ETI therapy pwCF prospectively scored AS on a daily basis with the CFAbd-day2day.
Results Altogether, n=45 pwCF attended in 5 CF centers prospectively completed the CFAbd-day2day before (mean±sd: −14±7 days) and after (mean±sd: 28±23 days) ETI initiation. Whereas cumulative scores significantly decreased during the 3-4-week time frame after ETI initiation, compared to the two weeks prior to therapy, many patients who revealed a relatively stable level of AS before ETI reported changes during the first days of treatment with the highly effective CFTR modulators. Items like pain and flatulence increased in up to 21% of patients during the first 14 days of therapy but they improved during days 15-27.
Conclusion The CFAbd-day2day, specifically developed and in process of validation to prospectively capture GI symptoms in pwCF, provides new substantial insights into the dynamics of AS in pwCF receiving a new treatment with ETI. The novel tool is also helpful to prospectively monitor patients with specific GI problems. International implementation and further validation steps of the diary are ongoing.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03052283
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been conducted in strict accordance with the ethical guidelines in the Declaration of Helsinki and, for Germany, it was approved by the Brandenburg Medical School ethics committee (Prof. Dr. Dr. Kurt J.G. Schmailzl, registration number: E-01-20200519).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
8 Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation
